Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : 3-DIMENSIONAL PHARMACEUTICALS (DDDP) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (30)	10/8/2001 8:59:40 AM
From: scaram(o)uche	Read Replies (1) \| Respond to of 146

Monday October 8, 8:32 am Eastern Time Press Release SOURCE: 3-Dimensional Pharmaceuticals, Inc. 3-Dimensional Pharmaceuticals Announces $4 Million Milestone Payment From Centocor in Connection with Thrombin Inhibitor Program EXTON, Pa., Oct. 8 /PRNewswire/ -- 3-Dimensional Pharmaceuticals, Inc. (Nasdaq: DDDP - news) today announced that it will receive a $4 million development milestone payment from Centocor, Inc., in connection with a collaboration agreement between the two companies to develop oral thrombin inhibitors. Centocor, a Johnson & Johnson company, acquired worldwide rights to 3-Dimensional Pharmaceutical's (3DP) orally active direct thrombin inhibitor program in December 2000. Centocor is responsible for development and worldwide commercialization of all compounds under the agreement. 3DP is eligible to receive milestone payments and royalties on sales of resulting products and retains an option to co-develop and co-promote the products for treatment of deep vein thrombosis in the United States. Since entering the collaboration, the companies have expanded it to include compounds against other targets in the coagulation cascade. ``3DP is very pleased to have reached this milestone,'' said David C. U'Prichard, Ph.D., 3DP's Chief Executive Officer. ``Since signing the agreement in December 2000, we have worked very closely with the Centocor team and are currently evaluating a full panel of thrombin inhibitors to determine which new product candidates to further develop. We see this milestone as a further validation of 3DP's technologies and expertise and look forward to a productive continuing relationship.'' 3DP (http://www.3dp.com) is an integrated bio-pharmaceuticals company dedicated to revolutionizing small molecule drug discovery and development. 3DP's proprietary platform, DiscoverWorks®, can be applied to virtually any potential drug target. It produces drug candidates suitable for faster development, with fewer resources and a higher probability of success than using conventional drug discovery methods. 3DP is developing its own drug pipeline and collaborates with other pharmaceutical companies in discovery and development. Statements in this press release that are not strictly historical are ``forward-looking'' statements which involve a high degree of risk and uncertainty. Such statements are only predictions, and the actual events of results may differ materially from those projected in such forward-looking statements. Factors that could cause or contribute to differences include, but are not limited to, risks associated with our new and uncertain technologies, clinical trials and product development, the long and arduous process of obtaining regulatory approval, our dependence on existing strategic alliances and new collaborations, our dependence on patents and proprietary rights, our ability to protect and enforce our patents and proprietary rights, the development and availability of competitive products or technologies, our ability to attract and retain talented employees and our ability to manage our expansion as a company increasingly focused on internal product research and development. SOURCE: 3-Dimensional Pharmaceuticals, Inc. (good news, whatever the hell it is)